Navigation Links
Amgen to Present at Lazard Capital Healthcare Conference
Date:11/16/2009

THOUSAND OAKS, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) will participate in the Lazard Capital Healthcare Conference on Wednesday, Nov. 18, 2009, at the St. Regis Hotel in New York City, beginning at 9:30 a.m. Eastern Time. Arvind Sood, vice president, Investor Relations at Amgen, will present at the conference. Live audio of the presentation will be available over the Internet and can be accessed from Amgen's Web site, www.amgen.com, under Investors.

Information regarding presentation time, webcast availability, and webcast links are available on Amgen's Investor Relations Events Calendar.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    CONTACT: Amgen, Thousand Oaks
    David Polk, 805-447-4613 or 805-490-0661 (media)
    Justin Claeys, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen


'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen Announces Webcast of 2009 Third Quarter Financial Results
2. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
3. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
5. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
6. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
7. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
8. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
9. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
10. Amgen to Present at the Cowen and Company Annual Healthcare Conference
11. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... fume hood and a high-performance fume hood. Along with the advantages and disadvantages ... for ductless vs. ducted hoods in the laboratory. , Attendees will learn from ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, ... PA, PhD in Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman ... years. They bonded over an interest in the potential of stem cell therapy and ...
(Date:9/19/2017)... Pleasanton, Calif. and Washington, D.C. (PRWEB) , ... ... ... to delivering rapid care during an biological outbreak is about to be eliminated, ... When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen ...
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen Analytical ... recipients of its 2017 Science Student Award. The scholarship program is dedicated to ... community service defray the costs of obtaining their science education. , Avomeen began ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):